Abstract：Objective To investigate the relationship of serum levels of pro-gastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) with chemotherapy efficacy and prognosis in patients with small cell lung cancer (SCLC). Methods A total of 103 SCLC patients who met the diagnostic criteria diagnosed in Oncology and Respiratory Department of Chengdu Fifth People′s Hospital from February 2016 to February 2017 were selected as study objects. Two cycles or more of the standard chemotherapy regimens were given to them. Serum ProGRP level was measured by enzyme-linked immunosorbent assay (ELISA), and serum NSE level was measured by electrochemiluminescence immunoassay (ECLIA). Taking the median serum ProGRP and NSE level as the boundary, the objects were divided into high ProGRP level group and low ProGRP level group, high NSE level group and low NSE level group, the relationship of the two indexes with efficacy and prognosis was analyzed. Results The serum levels of ProGRP and NSE in SCLC patients with tumor diameter ≥4 cm, extensive metastasis, distant metastasis and smoking history were higher than those in SCLC patients with tumor diameter ＜4 cm, limited clinical stage, no distant metastasis and no smoking history (P ＜ 0.05). The chemotherapeutic efficacy of low ProGRP level group was higher than that of high ProGRP level group, and PFS of low NSE level group was higher than that of high NSE level group. The factors affecting the prognosis of SCLC patients were clinical stage (OR = 4.986, 95%CI: 3.774-9.876, P = 0.003), distant metastasis (OR = 3.659, 95%CI: 2.182-7.569, P = 0.016) and serum NSE (OR = 2.879, 95%CI: 1.487-6.721, P = 0.005). Conclusion Serum ProGRP can predict the clinical efficacy of SCLC patients, serum NSE can predict the prognosis of SCLC patients. Two indicators should be evaluated comprehensively in clinical treatment, and close attention should be paid to SCLC patients with distant metastasis or extensive clinical stage.
2019, Vol. 16 
京公网安备 11010502046598号